Drug Price Trends for MICONAZOLE 7

Average Pharmacy Cost for MICONAZOLE 7

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
MICONAZOLE 7 CREAM	00904-7734-45	0.12302	GM	2026-07-22
MICONAZOLE 7 CREAM	24385-0590-29	0.12302	GM	2026-07-22
MICONAZOLE 7 CREAM	61269-0730-41	0.12302	GM	2026-07-22
MICONAZOLE 7 CREAM	61269-0730-63	0.12302	GM	2026-07-22
MICONAZOLE 7 CREAM	00904-7734-45	0.12399	GM	2026-06-17
MICONAZOLE 7 CREAM	24385-0590-29	0.12399	GM	2026-06-17
MICONAZOLE 7 CREAM	61269-0730-41	0.12399	GM	2026-06-17

Best Wholesale Price for MICONAZOLE 7

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
MICONAZOLE 7	United Drug Supply, Inc.	00113-0825-29	45GM	4.12	0.09156	GM	2023-12-01 - 2028-11-30	FSS
MICONAZOLE 7	United Drug Supply, Inc.	00113-0214-29	45GM	4.12	0.09156	GM	2023-12-01 - 2028-11-30	FSS

Miconazole 7 (Miconazole Nitrate Vaginal Products) Market Analysis and Price Projections: Demand, Competitor Pricing, and Generic/OTC Erosion Outlook

Last updated: July 16, 2026

Miconazole 7 refers to miconazole nitrate vaginal antifungal therapy sold in 7-day regimens (commonly branded as Monistat 7 in the US). Pricing is driven less by patent exclusivity and more by OTC vs Rx channel, private label competition, shelf velocity, and strengthening generic substitutes that compress margins as contracts and distribution scale. Over the next 3 to 5 years, price is expected to trend down modestly in the US retail channel and move with margin-sharing formulas in pharmacy benefit and institutional channels where miconazole 7 products are used.

What is Miconazole 7 and how is it sold (OTC, Rx, pack sizes, and active forms)?

Answer: Miconazole 7 is a vaginal antifungal regimen using miconazole nitrate (typically in insert/cream formats) delivered over a 7-day course. In the US, many products are OTC. The competitive set includes branded legacy products (notably Monistat 7) and numerous private label and generic equivalents.

Common product configurations

• Dosage form: vaginal cream and/or vaginal insert formats
• Treatment duration: 7 days
• Strength: miconazole nitrate (strength varies by specific label, e.g., mg/g for creams)
• Pack: single course (one 7-day pack)

Channel split that matters for pricing

• OTC retail: dominated by branded-to-generic/private label substitution cycles and promotions
• Online pharmacy and marketplace: higher price transparency accelerates discounting
• Professional/institutional purchasing: pricing follows formulary preferences when miconazole 7 is supplied as a standardized OTC-like product (less “brand premium,” more unit cost)

What patents or exclusivity control Miconazole 7 pricing, and when do they expire?

Answer: For “miconazole 7” products (miconazole nitrate vaginal therapy), market pricing is generally not protected by meaningful ongoing primary patent exclusivity in modern times because miconazole is an older, widely marketed antifungal. Price is therefore more exposed to generic and private label erosion than to long tail brand exclusivity.

Why exclusivity is usually not the dominant driver

• Miconazole is a mature molecule with extensive prior art and multiple marketed versions across decades.
• 7-day regimens are largely “standard-of-care” formats with broad design freedom (within safety/label constraints).
• Retail antifungal competition is frequently settled through formulation/presentation differences and pack architecture rather than hard exclusivity.

(No specific Orange Book patent list or expiration timetable is provided here because the prompt does not specify a particular listed NDC/brand pack, strength, or label variant.)

How many manufacturers sell Miconazole 7 in the US, and who sets the price floor?

Answer: The competitive floor is usually set by generic and private label offerings, while branded SKUs maintain the higher end through franchise trust and promotion intensity rather than patent leverage.

Price-setter dynamics by channel

• Retail mass: private label and generics determine the lowest shelf price; branded products anchor “comparison” pricing.
• Pharmacy chains: planograms and loyalty promotions create short bursts of discounting that compress the effective price for the category.
• E-commerce: generics and multi-pack bundle deals compress category ASP faster than brick-and-mortar.

What is the current pricing structure for Miconazole 7 (WAC, retail, and typical discount ranges)?

Answer: Miconazole 7 typically trades as a low-cost OTC antifungal category where retail pricing differences are modest in absolute dollars but meaningful in margin. The price hierarchy generally looks like:

1. Private label generics: lowest effective price
2. Generic branded/house brands: mid tier
3. Legacy branded franchise: highest nominal price, highest promotional intensity

How promotions distort projections

• Weekly ads, loyalty programs, and couponing can temporarily shift observed prices by single-digit percentage points to teens during promo windows.
• For market modeling, the sustainable baseline price is closer to the non-promo “everyday” price.

(No real-time price feeds were provided in the prompt; projections below are therefore structured as scenario ranges rather than a single numeric forecast.)

How do branded Monistat 7 and private label generics compare on price and market share?

Answer: Branded and franchise products generally command higher market share when inventory and shelf placement support them, but generics/private label usually drive the long-run unit-share trend in mature OTC antifungal categories.

Category forces that shift share

• Price elasticity: moderate, with consumer switching when the outcome is “similar enough”
• Store placement: endcaps and in-aisle “similar product” slots influence conversion
• Perceived efficacy: brand trust can slow decline but does not stop it in OTC switching environments

What do patent cliffs and generic entry risks look like for Miconazole 7?

Answer: The generic entry risk is not typically a discrete cliff tied to a single Paragraph IV event. The category’s competitive pressure is more continuous: incremental entrants appear via new NDCs, private label refresh cycles, and pack size changes, not through headline exclusivity expiration.

Regulatory pathway effect on pricing

• Where generic equivalents exist or can be launched as OTC-appropriate products, pricing tends to fall quickly after distribution acceptance.
• If a specific pack format is slower to replicate (e.g., a particular applicator or insert presentation), category pricing can hold temporarily.

(Again, the prompt does not specify an NDC, strength, or presentation. Without that, a precise “generic entry” risk map cannot be produced.)

What is the revenue exposure for Miconazole 7 across geographies (US vs EU/UK vs LATAM)?

Answer: The exposure in the US is the most measurable from a pricing and pharmacy ecosystem standpoint. In broader geographies, price and reimbursement differ substantially due to OTC rules and distribution structure.

US

• OTC retail drives volume.
• Competitive compression from generics/private label is persistent.

EU/UK

• OTC access varies by country.
• Parallel distribution and pharmacy discounting can produce faster price normalization where generics are entrenched.

LATAM

• Pricing may be supported longer by local branded products if generics penetration is lower, but tariffs, distribution, and reimbursement rules can shift outcomes.

How will demand evolve for vaginal antifungals treated as “7-day miconazole” products?

Answer: Demand is steady with seasonal softness and episodic spikes tied to women’s health cycles. Long-term category growth is typically limited; growth comes from:

• population growth
• diagnosis and treatment adherence
• availability through OTC channels

Key demand drivers for forecasting

• Incidence of vulvovaginal candidiasis
• Consumer switching across OTC antifungal durations (1-day, 3-day, 7-day)
• Treatment preference: some consumers and clinicians prefer longer regimens for perceived lower recurrence risk

Price projections for Miconazole 7: base, bearish, and bullish scenarios (3–5 year outlook)

Answer: In the absence of active exclusivity leverage, miconazole 7 pricing projections follow competitive intensity and promotion behavior. A reasonable forecast is:

• US retail baseline: low single-digit annual declines (net of promotions)
• US net price: potentially flatter than retail if manufacturers hold list price and increase trade spend
• E-commerce: sharper discounting, with greater year-over-year effective price pressure

Scenario table (effective price per unit)

Assuming a mature OTC category with ongoing generic/private label availability:

Horizon	Base case (YoY net price)	Bear case (YoY net price)	Bull case (YoY net price)
Year 1	-2% to -4%	-5% to -8%	-1% to -2%
Year 2	-1% to -3%	-4% to -7%	0% to -1%
Year 3	-1% to -2%	-3% to -6%	0% to -1%
Year 4-5	0% to -2%	-2% to -5%	0% to -1%

What causes faster price erosion

• Share shift toward private label
• More aggressive pharmacy loyalty promotions
• Pack-size changes that lower cost-per-course
• Retail consolidation increasing private label shelf space

What can stabilize pricing

• Strong branded franchise marketing support
• Reduced promotional frequency after normalization
• Supply chain improvements that reduce cost pass-through volatility
• Differentiated presentation that is slower to replicate

How does Miconazole 7 compare with other OTC vaginal antifungal regimens (1-day, 3-day, oral options)?

Answer: 7-day regimens face competition from shorter-course imidazole products (including other miconazole schedules and competing azoles). Price pressure increases when shorter regimens deliver perceived comparable outcomes at lower cost-per-treatment.

Competition by regimen length

• Short-course products attract price-sensitive switching.
• 7-day products retain share when consumers perceive lower recurrence or prefer traditional multi-day treatment.

What formulation, method-of-use, or delivery-system patents could still matter for Miconazole 7 pricing?

Answer: For a mature antifungal like miconazole, the only scenario where IP materially affects pricing is when a specific delivery system, applicator, or formulation is protected beyond the base molecule. Without an NDC-specific mapping, those patents cannot be enumerated here.

Patent estate categories to check for a specific NDC

• Formulation patents (vehicle, release characteristics)
• Device/applicator patents (insert/applies mechanism)
• Method-of-treatment claims (label-adjacent use patterns)
• Manufacturing process patents (less relevant to OTC pricing but relevant to litigation)

What litigation, settlements, or FDA actions affect Miconazole 7?

Answer: For an established OTC azole antifungal category, litigation is usually not a recurring driver of pricing unless it blocks a specific competitor’s entry or triggers supply withdrawals.

(No case-specific litigation dataset is included because the prompt does not define brand/NDC or the jurisdictional target.)

What Orange Book status should be expected for Miconazole 7?

Answer: For OTC vaginal products, the relevant regulatory listings vary. Many miconazole products are mature and may have limited or no active Orange Book coverage today for specific pack/NDCs.

(No Orange Book listing is provided because the prompt lacks the specific product identifier required to validate active listings.)

Commercial implications: what an entrant or investor should model

Answer: Treat Miconazole 7 as a distribution-and-promotion game more than an innovation game. Model unit economics assuming:

• fast onboarding into distribution with price-led acceptance
• limited willingness to pay for incremental brand premium over generics/private label
• persistent promotional cycles that drive realized net pricing below list

Investor/strategic modeling variables

• Effective price net of coupons and trade spend
• Net sales mix between branded vs private label
• Forecasted private label penetration
• Contract terms with major retailers
• Inventory turns and slotting costs

Key Takeaways

• Miconazole 7 pricing in the US is driven mainly by OTC retail competition, private label/generic availability, and promotion intensity, not by ongoing exclusivity.
• Expect net price erosion of low single digits annually in the base case over 3–5 years, with faster erosion in bearish scenarios tied to increased private label share and promo intensity.
• “Generic entry risk” is typically continuous in this category via new NDCs and pack formats, not a single patent cliff.
• For precise valuation or litigation/infringement risk, pricing projections should be tied to an exact product presentation (NDC/strength/pack) to map any formulation or device IP.

FAQs

1. How do 7-day miconazole products price versus 1-day and 3-day azole vaginal antifungals?
   Short-course regimens usually exert greater price pressure by offering lower cost-per-course and easier adherence.

2. What drives the largest changes in realized net price for OTC antifungals?
   Retail promotions, loyalty program discounts, and trade spend reallocations typically dominate year-over-year changes.

3. Do miconazole 7 private labels typically undercut branded products by a predictable percentage?
   The discount varies by retailer and promo calendar, but private label generally anchors the lower end of the shelf-price range.

4. Is there a meaningful Paragraph IV play for miconazole 7 vaginal products?
   Often not a discrete event in a mature OTC category; entry is more commonly shaped by generic/private label launches and pack-level availability.

5. How should an investor model volume changes for miconazole 7 if competitors introduce shorter regimens?
   Model share reallocation rather than total category growth, with volume shifting toward lower cost-per-treatment schedules when consumers perceive comparable outcomes.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
2. FDA. OTC Drug Product Database / Drug approvals and labeling records. (Accessed via FDA databases).